Novartis has been granted 5 years of exclusive marketing rights (EMR) for imatinib mesylate [Glivec] in India

Author:  

Publisher: Adis International

ISSN: 1173-8324

Source: Inpharma, Vol.1, Iss.1416, 2003-01, pp. : 22-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract